Endometrial Cancer Market Size 2025-2035, Epidemiology, Drugs Treatment & Companies

 The endometrial cancer market reached a value of USD 21.4 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 31.5 Billion by 2035, exhibiting a growth rate (CAGR) of 3.62% during 2025-2035.



In-demand therapies, increasing diagnoses, and advanced technology are all contributing to the steady growth of the endometrial cancer market in 2025. Shift towards more tailored strategies is becoming evident as detection and treatment technologies continue to evolve.

One of the most common cancer types across the globe due to the rising obesity, diabetes, and age demographics is Endometrial cancer. Early case detection using pelvic ultrasound, hysteroscopy, CT scan as well MRI aids uncovering previously unnoticed cases. Campaigns centered around women’s healthcare are increasingly encouraging women to seek care leading to a greater number of confirmed diagnoses.

Advanced surgical methodologies and precision medicine are further propelling the global endometrial cancer market in 2025. Laparoscopic and robotic-assisted hysterectomies became commonplace due to better recovery profiles. With mainstream genetic profiling and biomarker testing, clinicians can now tailor treatment strategies to the patient's tumor biology. In immunotherapy, checkpoint inhibitors like dostarlimab (Jemperli), durvalumab (Imfinzi), and pembrolizumab (Keytruda) are given as standard therapy, especially for advanced or recurrent disease with mismatch repair deficiency. Progression-free survival is greatly improved with these drugs when used in conjunction with chemotherapy.
Antibody–drug conjugates (ADCs) designed as trastuzumab‑deruxtecan and Elahere have early activity in HER2-positive tumors which both diagnose cancers earlier and treat them more carefully to harm healthy tissues less, thus incurring fewer side effects. Early-stage disease also benefits from endocrine therapies like levonorgestrel intrauterine device (LNG-IUD), which has low side effects making it a viable option. Such changes show a market working towards treating patients with greater accuracy by moving away from chemotherapy towards more tailored therapeutics.

Request for a sample of this report: https://www.imarcgroup.com/endometrial-cancer-market/requestsample

Countries Covered:

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country:

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the endometrial cancer market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the endometrial cancer market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs

This report also provides a detailed analysis of the current endometrial cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs:

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

  • Drug overview
  • Mechanism of action
  • Regulatory status
  • Clinical trial results
  • Drug uptake and market performance

Competitive Landscape with key players:

The competitive landscape of the endometrial cancer market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Merck & Co

2. GlaxoSmithKline

3. Eisai Co Ltd/Merck & Co

4. Genentech

5. Incyte Corporation/Macrogenics

6. Karyopharm Therapeutics

7. Evergreen Therapeutics

8. Byondis

Explore the Full Report with TOC: Endometrial Cancer Treatment Market Epidemiology

Countries Covered

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145


Comments

Post a Comment

Popular posts from this blog

Cancer Pain Market Size, Epidemiology, Trends, and Forecast 2025

Image
  The   cancer pain market size   reached a value of USD 1,778.2 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 2,625.8 Million by 2035, exhibiting a growth rate (CAGR) of 3.61% during 2025-2035. The year of 2025 may see the cancer pain market in a raging state, made dynamic from the rise in cancer cases, changing treatment strategies, and significant technological progress. Cancer pain afflicts approximately 53% of all individuals diagnosed with the disease and 64% of those who have the illness at the advanced stage, holding a central position in oncology care. With increasing global cancer incidence, the demand for effective and patient-friendly management of pain has never been higher. A major factor responsible for this expansion is the rising prevalence of cancer worldwide. As the population ages and lifestyle-related risk factors increase, more and more people are getting d...
Read more

Obstructive Sleep Apnea Market Size, Epidemiology, Trends, and Forecast

Image
The 7 major  obstructive sleep apnea markets size  reached a value of USD 794.9 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 4,066.7 Million by 2035, exhibiting a growth rate (CAGR) of 16.2% during 2025-2035. Increased global awareness, increasing incidence rates, and technological advancements are largely contributing to the growth of the OSA market in 2025. Sleep apnea refers to periodic arousals from sleep accompanied by cessation of breathing and is a common ailment affecting millions of people across the globe. With increasing awareness about associated health risks such as hypertension, cardiovascular diseases, and diabetes, the demand for diagnosis and treatment on time is rapidly increasing.  One of the leading causes of market growth is the increasing incidences of sleep apnea. In the name of modern lifestyles, with instances of poor sleep hygiene, sedentary behavior, and increased calorie intake, sleep apnea cases are surging a...
Read more

Exocrine Pancreatic Insufficiency Market Epidemiology Report 2024-2034 | Treatment & Rising Incidence

Image
  The 7 major  exocrine pancreatic insufficiency markets size  reached a value of US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.0 Billion by 2034, exhibiting a growth rate (CAGR) of 5.15% during 2024-2034. The 2025 market for exocrine pancreatic insufficiency  (EPI) captures increased awareness, new treatments, and patient-focused models of care. EPI, a disease characterized by the insufficient production of digestive enzymes, is seen in individuals with chronic pancreatitis, cystic fibrosis, or other gastrointestinal conditions. With increased awareness, clinicians are focusing on improved diagnosis, therapy choices, and continued support of patients. Improvement of enzymatic replacement therapies is one of the most powerful trends in 2025. New formulations of pancreatic enzyme products have more accurate dosing and fewer side effects. By customizing enzyme mixtures based on individual food habits and digestion requirements, pa...
Read more